DE60307490D1 - Schutz eines Patienten vor möglichen Nebenwirkungen entstanden durch die Verhinderung der SHH-CASCADE indem Testosteron unterdrückt wird - Google Patents
Schutz eines Patienten vor möglichen Nebenwirkungen entstanden durch die Verhinderung der SHH-CASCADE indem Testosteron unterdrückt wirdInfo
- Publication number
- DE60307490D1 DE60307490D1 DE60307490T DE60307490T DE60307490D1 DE 60307490 D1 DE60307490 D1 DE 60307490D1 DE 60307490 T DE60307490 T DE 60307490T DE 60307490 T DE60307490 T DE 60307490T DE 60307490 D1 DE60307490 D1 DE 60307490D1
- Authority
- DE
- Germany
- Prior art keywords
- patient
- shh
- protecting
- cascade
- testosterone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0221539 | 2002-09-17 | ||
GBGB0221539.0A GB0221539D0 (en) | 2002-09-17 | 2002-09-17 | Methods of treatment |
PCT/GB2003/004117 WO2004026304A1 (en) | 2002-09-17 | 2003-09-17 | An inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60307490D1 true DE60307490D1 (de) | 2006-09-21 |
DE60307490T2 DE60307490T2 (de) | 2007-03-29 |
Family
ID=9944217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60307490T Expired - Fee Related DE60307490T2 (de) | 2002-09-17 | 2003-09-17 | Schutz eines Patienten vor möglichen Nebenwirkungen entstanden durch die Verhinderung der SHH-CASCADE indem Testosteron unterdrückt wird |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060094660A1 (de) |
EP (1) | EP1549308B1 (de) |
JP (1) | JP2006503055A (de) |
AT (1) | ATE335478T1 (de) |
AU (1) | AU2003267623A1 (de) |
DE (1) | DE60307490T2 (de) |
ES (1) | ES2274259T3 (de) |
GB (1) | GB0221539D0 (de) |
WO (1) | WO2004026304A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2578728T3 (es) * | 2004-08-27 | 2016-07-29 | Infinity Pharmaceuticals, Inc. | Proceso para la preparación de compuestos análogos de ciclopamina |
US20110034498A1 (en) * | 2006-03-24 | 2011-02-10 | Mcgovern Karen J | Dosing regimens for the treatment of cancer |
WO2007136250A2 (en) * | 2006-05-24 | 2007-11-29 | Stichting Voor De Technische Wetenschappen | A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
BRPI0808444A2 (pt) | 2007-03-07 | 2017-06-06 | Infinity Discovery Inc | análogos de ciclopamina lactam e métodos de uso dos mesmos |
JP2010520295A (ja) * | 2007-03-07 | 2010-06-10 | インフィニティ・ディスカバリー・インコーポレイテッド | へテロ環状シクロパミン類似体及びその使用方法 |
US8669243B2 (en) * | 2007-10-30 | 2014-03-11 | The Wistar Institute | Steroid-derived cyclopamine analogs and methods for using the same in the prevention or treatment of cancer |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
AU2008345097A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
AR070047A1 (es) * | 2007-12-27 | 2010-03-10 | Infinity Pharmaceuticals Inc | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. |
WO2009132032A2 (en) * | 2008-04-21 | 2009-10-29 | President And Fellows Of Harvard College | Sonic hedgehog modulators |
ES2567134T3 (es) | 2009-08-05 | 2016-04-20 | Infinity Pharmaceuticals, Inc. | Transaminación enzimática de análogos de ciclopamina |
WO2011057222A1 (en) * | 2009-11-06 | 2011-05-12 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
JP6796638B2 (ja) | 2015-06-04 | 2020-12-09 | ペレファーム, インク.Pellepharm, Inc. | ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1171374A (en) * | 1981-04-13 | 1984-07-24 | Takeda Chemical Industries, Ltd. | Pseudo-aminosugars, their production and use |
AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
JP5196700B2 (ja) * | 2000-10-13 | 2013-05-15 | キュリス,インコーポレイテッド | ヘッジホッグアンタゴニスト、それらに関する方法及び利用 |
-
2002
- 2002-09-17 GB GBGB0221539.0A patent/GB0221539D0/en not_active Ceased
-
2003
- 2003-09-17 WO PCT/GB2003/004117 patent/WO2004026304A1/en active IP Right Grant
- 2003-09-17 AT AT03748315T patent/ATE335478T1/de not_active IP Right Cessation
- 2003-09-17 JP JP2004537316A patent/JP2006503055A/ja active Pending
- 2003-09-17 AU AU2003267623A patent/AU2003267623A1/en not_active Abandoned
- 2003-09-17 DE DE60307490T patent/DE60307490T2/de not_active Expired - Fee Related
- 2003-09-17 ES ES03748315T patent/ES2274259T3/es not_active Expired - Lifetime
- 2003-09-17 US US10/528,267 patent/US20060094660A1/en not_active Abandoned
- 2003-09-17 EP EP03748315A patent/EP1549308B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE335478T1 (de) | 2006-09-15 |
JP2006503055A (ja) | 2006-01-26 |
AU2003267623A1 (en) | 2004-04-08 |
EP1549308A1 (de) | 2005-07-06 |
US20060094660A1 (en) | 2006-05-04 |
GB0221539D0 (en) | 2002-10-23 |
WO2004026304A1 (en) | 2004-04-01 |
ES2274259T3 (es) | 2007-05-16 |
EP1549308B1 (de) | 2006-08-09 |
DE60307490T2 (de) | 2007-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60307490D1 (de) | Schutz eines Patienten vor möglichen Nebenwirkungen entstanden durch die Verhinderung der SHH-CASCADE indem Testosteron unterdrückt wird | |
BRPI0617165A2 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
CL2021002100A1 (es) | Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1. | |
CY1108725T1 (el) | Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
TW200716183A (en) | Parakeratosis inhibitor, pore-contracting agent and external composition for skin | |
MXPA04002167A (es) | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
NO20090144L (no) | Heterosykliske aspartylproteaseinhibitorer | |
WO2005000213A3 (en) | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors | |
WO2003090681A3 (en) | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS | |
MX2009006228A (es) | Inhibidores de aspartil proteasa. | |
MX2023006145A (es) | Inhibidores de prmt5 novedosos. | |
TW200509949A (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
BRPI0916540B8 (pt) | inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos | |
TNSN07193A1 (en) | Pharmaceutical compositions comprising a camptothecin derivate | |
WO2005000212A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors | |
WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
EP1628667A4 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
WO2004038001A3 (en) | Substituted tetracycline compounds for the treatment of malaria | |
EA200800766A1 (ru) | Ингибиторы pi3k для лечения эндометриоза | |
ES2181366T3 (es) | Derivados de piperidina que tienen efectos sobre sistemas relacionados con serotonina. | |
MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
WO2003059254A3 (en) | Prevention and treatment of atherosclerosis and restenosis | |
PT1206444E (pt) | Compostos que inibem a actividade da triptase | |
UA96736C2 (ru) | Ингибиторы pi3k для лечения эндометриоза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |